◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 0660

Wai Chun Bio-Technology Limited (0660) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Basic Materials · Chemicals · DATA UPDATED 2026-08-10

Wai Chun Bio-Technology Limited (0660) operates in the Chemicals industry and is headquartered in Wan Chai, Hong Kong with about 63 employees. Its market capitalization is roughly HKD 188 million. In the fiscal year ended 2025-06-30, 0660 reported HKD 377M in revenue and (HKD 15M) in net income.

Wai Chun Bio-Technology Limited, an investment holding company, engages in the manufacture and sale of modified starch and other biochemical products in the People's Republic of China.

Interactive charts & full statements →

0660 Revenue & Earnings History — Annual Income Statement

Income statement2025-06-302024-06-302023-06-302021-12-31
Total RevenueHKD 377MHKD 370MHKD 774MHKD 495M
Gross ProfitHKD 36MHKD 34MHKD 50MHKD 38M
Operating Income (EBIT)HKD 1MHKD 1MHKD 14MHKD 2M
Net Income(HKD 15M)(HKD 44M)(HKD 15M)(HKD 17M)

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0660 Free Cash Flow History

0660 Balance Sheet History

Balance sheet2025-06-302024-06-302023-06-302022-06-302021-12-31
Total AssetsHKD 215MHKD 210MHKD 240MHKD 250M
Total LiabilitiesHKD 277MHKD 265MHKD 230MHKD 244M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0660 viewer.

Other Companies in Chemicals

← 0659All “0-9” companies0661 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.